Market Overview

Kensey Nash Introduces A Novel Biomaterial, Meso BioMatrix Acellular Porcine Peritoneum, For Plastic And Reconstructive Surgery


Kensey Nash Corporation (Nasdaq: KNSY) today announced the achievement of several milestones for its Meso BioMatrix™ surgical mesh including the first clinical implant of the product. The Meso BioMatrix™ product is indicated for use in the United States for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair and reinforcement in plastic and reconstructive surgery. The procedure was performed by Dennis Hammond, M.D. of Partners in Plastic Surgery in Grand Rapids, Michigan. "The Meso BioMatrix™ product offers several advantages for use in plastic and reconstructive surgery including strength with just the right amount of pliability, and easy re-draping around corners and complex contours. It will serve as an excellent adjunct in plastic and reconstructive surgery," commented Dr. Hammond.

Kensey Nash will be exhibiting the Meso BioMatrix™ product May 5th-7th at the American Society of Aesthetic Plastic Surgery Meeting in Vancouver, BC.

Posted-In: News FDA


Related Articles (KNSY)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Market Astrology: Another Economic Downturn?

Whitestone REIT Reports 3% Increase in Occupancy Q1 2012 Versus Q1 2011